Gainers

  • Regional Health Properties Inc RHErose 152.6 percent to $0.34 in pre-market trading after the announcement that the company will forbear from exercising its right to accelerate outstanding loans.
  • Foamix Pharmaceuticals Ltd.FOMX rose 47.8 percent to $8.75 in pre-market trading after the company disclosed that a Phase 3 trial for the company’s FMX101 acne candidate met both co-primary endpoints.
  • Galapagos NV GLPGshares rose 15.6 percent to $118.79 in pre-market trading. Gilead and Galapagos disclosed that Filgotinib met primary and ‘all key secondary’ endpoints in Phase 3 study in rheumatoid arthritis.
  • Alliqua BioMedical, Inc.ALQA rose 15.6 percent to $2.96 in pre-market trading after declining 3.20 percent on Tuesday.
  • Akari Therapeutics, Plc AKTX 0.48%rose 12.6 percent to $2.33 after the company announced preclinical data demonstrating positive effects of coversin in rheumatoid arthritis.
  • Bausch Health Companies Inc.BHC shares rose 8.6 percent to $22.44 in pre-market trading after the company’s subsidiary, Salix, announced resolution of XIFAXAN intellectual property litigation.
  • Turtle Beach Corporation HEARshares rose 8.3 percent to $25.34 in pre-market trading after falling 7.03 percent on Tuesday.
  • EyePoint Pharmaceuticals, Inc.EYPT rose 8.3 percent to $2.48 in pre-market trading following Q4 results.
  • Tilray, Inc.TLRY rose 7.6 percent to $103.00 in pre-market trading after surging 13.36 percent on Tuesday.
  • Foresight Autonomous Holdings Ltd.NASDAQFRSX shares rose 6.9 percent to $2.97 in pre-market trading.
  • Cardlytics, Inc.CDLX rose 5.4 percent to $25.72 in pre-market trading after gaining 15.48 percent on Tuesday.
  • Coca-Cola European Partners plc CCErose 4.5 percent to $45.19 in pre-market trading.
  • Northern Oil and Gas, Inc.NOG shares rose 4.4 percent to $3.31 in pre-market after reporting strong preliminary production for July and August, 2018.
  • Pacific Biosciences of California, Inc.PACB rose 4.1 percent to $4.75 in pre-market trading. Pacific Biosciences priced its 14.1 million share public offering of common stock at $4.25 per share.
  • Gilead Sciences, Inc. GILDrose 3.4 percent to $74.69 in pre-market trading. Gilead and Galapagos disclosed that Filgotinib met primary and ‘all key secondary’ endpoints in Phase 3 study in rheumatoid arthritis.
  • Chesapeake Energy Corporation CHKrose 3 percent to $4.18 in pre-market trading.
  • Sonos, Inc.SONO shares rose 2.7 percent to $17.00 in pre-market trading after dropping 22.03 percent on Tuesday.

 

Losers

  • Vital Therapies IncVTL fell 88.9 percent to $0.70 in pre-market trading after the company reported that topline results of VTL-308 failed to achieve primary and secondary endpoints of improvement in survival.
  • PGT Innovations, Inc.PGTI shares fell 7.9 percent to $24 in pre-market trading after the company reported a 7 million share common stock offering.
  • Riot Blockchain, Inc.RIOT shares fell 6.8 percent to $4 in pre-market trading after dropping 4.67 percent on Tuesday.
  • ArQule, Inc.ARQL shares fell 6.6 percent to $5.50 in pre-market trading after declining 3.28 percent on Tuesday.
  • Farmer Bros CoFARM shares fell 6 percent to $26.70 in pre-market after reporting downbeat results for its fourth quarter on Tuesday.
  • Catalyst Pharmaceuticals, Inc.CPRX fell 4.7 percent to $3.05 in pre-market trading after dropping 3.03 percent on Tuesday.
  • Snap Inc. SNAPfell 4.4 percent to $9.46 in pre-market trading. BTIG Research downgraded Snap from Neutral to Sell.
  • BeiGene, Ltd.BGNE fell 4.2 percent to $159.80 in pre-market trading.
  • Micron Technology, Inc.MU fell 3.7 percent to $42.00 in pre-market trading after dropping 2.90 percent on Tuesday.
  • WABCO Holdings Inc.WBC fell 3.5 percent to $120 in pre-market trading.
  • Zscaler, Inc.ZS shares fell 3.4 percent to $41.50 in pre-market trading after declining 6.14 percent on Tuesday.
  • Pinduoduo Inc.PDD fell 3.3 percent to $22.81 in pre-market trading after climbing 19.40 percent on Tuesday.
  • Annaly Capital Management, Inc.NLY fell 2.8 percent to $10.19 in pre-market trading. Annaly Capital Management priced its 75 million share common offering for gross proceeds of $750 million.